Immunogenetic mechanisms driving norovirus GII.4 antigenic variation by Lindesmith, Lisa C. et al.
Immunogenetic Mechanisms Driving Norovirus GII.4
Antigenic Variation
Lisa C. Lindesmith1., Martina Beltramello2., Eric F. Donaldson1, Davide Corti2,3, Jesica Swanstrom1,
Kari Debbink1, Antonio Lanzavecchia2, Ralph S. Baric1*
1Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, United States of America, 2 Institute for Research in Biomedicine, Bellinzona,
Switzerland, 3Humabs Biomed SA, Bellinzona, Switzerland
Abstract
Noroviruses are the principal cause of epidemic gastroenteritis worldwide with GII.4 strains accounting for 80% of infections.
The major capsid protein of GII.4 strains is evolving rapidly, resulting in new epidemic strains with altered antigenic
potentials. To test if antigenic drift may contribute to GII.4 persistence, human memory B cells were immortalized and the
resulting human monoclonal antibodies (mAbs) characterized for reactivity to a panel of time-ordered GII.4 virus-like
particles (VLPs). Reflecting the complex exposure history of the volunteer, human anti-GII.4 mAbs grouped into three VLP
reactivity patterns; ancestral (1987–1997), contemporary (2004–2009), and broad (1987–2009). NVB 114 reacted exclusively
to the earliest GII.4 VLPs by EIA and blockade. NVB 97 specifically bound and blocked only contemporary GII.4 VLPs, while
NBV 111 and 43.9 exclusively reacted with and blocked variants of the GII.4.2006 Minerva strain. Three mAbs had broad GII.4
reactivity. Two, NVB 37.10 and 61.3, also detected other genogroup II VLPs by EIA but did not block any VLP interactions
with carbohydrate ligands. NVB 71.4 cross-neutralized the panel of time-ordered GII.4 VLPs, as measured by VLP-
carbohydrate blockade assays. Using mutant VLPs designed to alter predicted antigenic epitopes, two evolving, GII.4-
specific, blockade epitopes were mapped. Amino acids 294–298 and 368–372 were required for binding NVB 114, 111 and
43.9 mAbs. Amino acids 393–395 were essential for binding NVB 97, supporting earlier correlations between antibody
blockade escape and carbohydrate binding variation. These data inform VLP vaccine design, provide a strategy for
expanding the cross-blockade potential of chimeric VLP vaccines, and identify an antibody with broadly neutralizing
therapeutic potential for the treatment of human disease. Moreover, these data support the hypothesis that GII.4 norovirus
evolution is heavily influenced by antigenic variation of neutralizing epitopes and consequently, antibody-driven receptor
switching; thus, protective herd immunity is a driving force in norovirus molecular evolution.
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Introduction
Noroviruses (NoVs) are the leading cause of severe viral
gastroenteritis and are responsible for 50% of all acute gastroen-
teritis outbreaks in the United States and Europe [1]. Although the
severity of disease is usually moderate, lasting 1–3 days, infection
can be especially virulent in young children, the elderly, and the
immunocompromised, with the latter group experiencing chronic
diarrhea and virus shedding for over a year [2–8]. Importantly, it
is estimated that 200,000 people die each year from norovirus
infections, primarily children in the developing world [9]. An
effective vaccine would be particularly advantageous for the very
young and aged populations, military personnel, children and
healthcare providers, food handlers, cruise ship passengers, and
populations of the developing world [10]. Immunotherapeutics are
especially needed for treating immunosuppressed populations
experiencing long-term infections with chronic diarrhea. The lack
of understanding of the extensive antigenic relationships among
the large number of norovirus strains and the complex relationship
between host protective immunity and virus antigenic heteroge-
neity are the primary obstacles to norovirus vaccine development.
Noroviruses are ,38 nm icosahedral viruses with a ,7.5 kb
single-stranded, positive-sense RNA genome that contains three
large open reading frames (ORFs). ORF1 encodes the non-structural
proteins, while ORFs 2 and 3 encode the major and minor capsid
proteins respectively. Expression of the major capsid protein (ORF2)
in Venezuelan equine encephalitis (VEE) virus or baculovirus results
in the formation of virus-like particles (VLPs) composed of 90 copies
of the major capsid protein dimer [11]. Noroviruses are grouped by
the amino acid sequence of the major capsid protein: viruses with less
than 14.3% difference are classified as the same strain, 14.3–43.8%
difference as the same genotype, and 45–61.4% difference as the
same genogroup [12]. Currently, noroviruses are grouped into five
genogroups (GI–GV). Genogroups GI and GII are responsible for
most human infections and are further subdivided into 8 and 21
different genotypes, respectively [1,12].
Structurally, the capsid monomer is divided into three domains.
The shell domain (S) forms the core of the particle and the
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protruding domain (P) extends away from the core. The P domain
is further subdivided into the P1 subdomain (residues 226–278 and
406–520) and the P2 subdomain (residues 279–405) [11]. The P2
subdomain is the most exposed region of the viral particle and is
well positioned to interact with potential neutralizing antibodies
and histoblood group antigen (HBGA) ligands [13–17]. Previous
studies have shown that the P2 subdomain of the major capsid
protein of GII.4 strains is evolving rapidly, resulting in new
epidemic strains with altered carbohydrate ligand binding
properties and antigenicity [13,18–23].
For the past two decades, the majority of norovirus outbreaks
have been caused by strains within the genogroup II, genotype 4
(GII.4 strains) subcluster. Between 1995 and 2006, four major
norovirus pandemics associated with GII.4 strains were charac-
terized using molecular epidemiologic methods. During the mid-
1990’s [24] strain US95/96 was responsible for ,55% of the
norovirus outbreaks in the USA and 85% of the outbreaks in the
Netherlands [25]. In 2002, the US95/96 strain was replaced by
the Farmington Hills strain [26], which was associated with,80%
of norovirus outbreaks [27] in the USA. In 2004, the Hunter GII.4
variant was detected in Australia, Europe, and Asia [28–30].
Hunter strains were largely replaced in 2006 by two new co-
circulating GII.4 variants in the USA and Europe, Laurens
(2006a) and Minerva (2006b) [5,29,31]. Although similar to
Minerva, Apeldoorn317 (GII.4.2008, GenBank accession
no. AB445395) represents a new evolutionary cluster in the
phylogeny of the GII.4 viruses. Most recently, a new GII.4.2006
variant, GII.4.2009 New Orleans, has been the predominate
outbreak strain, although GII.4.2006 Minerva continues to
circulate at low levels [1,32].
A variety of studies using time ordered human outbreak sera
and mouse monoclonal antibodies support the hypothesis that the
GII.4 noroviruses are undergoing antigenic variation and that this
variation contributes to the emergence of new outbreak strains
over time [13,22,33,34]. However, the lack of a cell culture or
small animal model for human norovirus cultivation restricts study
of neutralization antibodies and epitopes. To circumvent this
problem, highly informative in vitro assays have been developed
that measure the ability of an antibody to ‘‘block’’ binding of a
VLP to a carbohydrate ligand [13,35,36]. This assay is highly
sensitive, as it differentiates between norovirus strains too similar
to be distinguished by enzyme immunoassay (EIA). The clinical
relevance of the blockade assay, as a surrogate neutralization
assay, has been confirmed in both infected chimpanzees [37] and
Norwalk virus-infected humans [10,38]. For NoV strains that
hemagglutinate RBCs, high blockade antibody titers that prevent
hemagglutination also correlate with protection from disease in
humans [39]. Using human norovirus outbreak sera, VLP-
immunized mouse sera, and mouse mAbs [13,33,34], the early
GII.4 strains (1987 and 1997) were antigenically indistinguishable
from each other by EIA and surrogate neutralization assays. VLPs
of strains circulating post 2002 had significantly less reactivity with
sera directed against earlier strains and no reactivity to mouse
mAbs directed to GII.4.1987. Conversely, select mouse mAbs
generated against GII.4.2006 reacted with VLPs that circulated
only from 2002 or later. No blockade epitopes were found to be in
common between GII.4.1987 and GII.4.2006.
Prior to this work, we and others had predicted GII.4 antibody
epitopes using bioinformatic techniques. As expected, discreet
amino acids are repeatedly identified as potential evolving
epitopes. In particular, residues 296–298 and 393–395 are
consistently identified as putative epitopes that change between
epidemic GII.4 strains. Additional surface residues at 333, 340,
356, 368, 372, 407 and 412–413 were also predicted as potential
antibody epitopes [13,18,19,22,28,40–42]. These amino acids
tend to cluster on loops and ridges of the P2 subdomain where
antibody interaction would be most accessible. Beyond bioinfor-
matics predictions, only a few studies have shown empirical
evidence mapping GII.4 antigenic change. Allen et al. [42]
compared the reactivity of five monoclonal antibodies against a
pre and post-2002 epidemic GII.4 strain, and identified confor-
mational epitopes composed of residues 294–296 and 393–395.
The carbohydrate blockade potential of these antibodies was not
reported, so the role of these sites in escape from herd immunity
was unclear. However, the finding that residues 393–395 were
antigenically important supported our previously published work
identifying amino acid 395 as an antigenic determinant in the
GII.4.2002 Farmington Hills strain [13]. Using mouse mAbs and
molecular biology approaches to exchange predicted epitopes
between GII.4 strain backbones, we have clearly identified amino
acids 294, 296–298, 368 and 372 to comprise an evolving
blockade epitope, as exchange of these amino acids from
GII.4.1987 into GII.4.2006 conferred binding of mAbs that
recognize GII.4.1987 but not GII.2006 [43]. Extending this
approach, we have also confirmed amino acids 407, 412 and 413
to constitute a GII.4.2002 Farmington Hills-specific blockade
epitope [17]. These empirical studies support the validity of using
computational analysis to guide norovirus epitope studies.
Comparing reactivity of polyclonal sera collected from immu-
nized mice and infected humans suggested antigenic variation
within the GII.4 noroviruses [13,33]. The development of mouse
mAbs to different time-ordered GII.4 VLPs has greatly facilitated
progress towards understanding the complex antigenic relations
among these strains by clearly demonstrating antigenic variation
over time and epidemic strain [34,42,43]. However, to maximally
define the mechanistic relationships that exist between antigenic
variation, immunity, and HBGA binding patterns noted in the
GII.4 noroviruses in the context of natural infection history, the
cross reactivity patterns, blockade responses, and epitope targets of
human anti-GII.4 monoclonal antibodies are needed. Robust
approaches exist for the isolation of human monoclonal antibodies
that are elicited following virus infection. Using human PBMCs as
Author Summary
Noroviruses are the principal cause of epidemic gastroen-
teritis worldwide with GII.4 strains accounting for 80% of
infections. The major capsid protein of GII.4 strains is
evolving rapidly, resulting in new epidemic strains with
altered antigenic sites. To define these sites we prepared
the first human monoclonal antibodies (Hu mAbs) against
GII.4 noroviruses by immortalizing memory B cells and
characterizing antibody reactivity and carbohydrate block-
ade responses across a ,20 year panel of time-ordered
GII.4 virus-like particles (VLPs). Reflecting the complex
exposure history of the patient, human anti-GII.4 mAbs
grouped into three VLP reactivity patterns: broad (1987–
2009), contemporary (2004–2009), and ancestral (1987–
2002). We also identified the location of several defined
epitopes which evolve over time and drive antigenic
change. Our data indicate that antibodies targeting these
sites block carbohydrate binding and likely select for the
emergence of new strains that escape herd immunity and
recognize unique carbohydrates for entry, resulting in new
outbreaks of disease in vulnerable human populations.
Importantly, these studies critically inform the rational
design of broadly active vaccines and immunotherapeutics
for the treatment of norovirus disease.
GII.4 Norovirus Human Monoclonal Antibodies
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a source of memory B cells, we created a panel of human mAbs
directed against GII.4 strains and compared the reactivity of these
mAbs to a panel of time-ordered GII.4 VLPs using EIAs and
surrogate neutralization assays. We identified one novel, broadly
cross reactive antibody that differentially blocks GII.4.1987
through 2009 VLP interactions with carbohydrate ligands, a
potential immunotherapeutic for the treatment of acute or chronic
GII.4 disease. We also defined unique antibody interactions with
two different surface exposed epitopes that evolve over time.
Importantly, antigenic variation in one of these epitopes correlated
with changing carbohydrate ligand binding patterns over time,
supporting the proposed relationship between epitope escape from
human herd immunity and changing HBGA usage for virus
docking [13]. In addition to defining the first human monoclonal
antibodies with therapeutic potential for treating acute and
chronic NoV GII.4 infections, these data support the hypothesis
that GII.4 norovirus evolution results in antigenic drift of
neutralizing epitopes and consequently, antibody-driven HBGA
receptor switching; thus, protective herd immunity is a driving
force in norovirus evolution.
Results
Donor sample characterization and mAb isolation
The development of mouse mAbs against different time-ordered
GII.4 VLPs has greatly facilitated understanding of the complex
antigenic relations between these strains by clearly demonstrating
antigenic variation over time and by epidemic strain [34].
However, understanding of the human anti-GII.4 norovirus
antibody response is essential not only for understanding the
complex relationships between host immunity and virus antigenic
change, but also for rational vaccine design based on defined
neutralizing epitopes. Therefore, we developed a panel of human
anti-GII.4 norovirus monoclonal antibodies to begin to charac-
terize GII.4 antibody reactivity in the native virus host under
natural infection conditions, noting that the norovirus pre-
exposure histories in human volunteers are unknown and can
only be inferred by human sera cross-reactive antibody binding
and blockade patterns using time-ordered VLPs representing
different outbreak and pandemic strains (Table 1) [13,33]. Plasma
and PBMC samples from 63 healthy individuals were collected in
early 2009 and plasma binding titers (ED50) were measured by
EIA against a panel of 6 different norovirus VLPs representing GI
and GII strains (Figure 1). The majority of tested samples reacted
by EIA with variable ED50 titers to the panel of VLPs tested
(Figure S1). One sample (Donor NVB) was shown to react strongly
with GII VLPs and was therefore chosen for further character-
Table 1. NoV Strains (VLPs) used in this study.
VLP Pandemic Cluster GenBank Access. No. Original Strain
GI.1.1968 None M87661 Outbreak Isolate
GI.1.2001 None AY502016 Hu/NoV/West Chester/2001/USA
GI.2.1999 None JQ743332 Outbreak Isolate
GI.3.1999 None JQ743330 Outbreak Isolate
GI.4.2000 None JQ743331 Outbreak Isolate
GII.1.1971 None U07611 Outbreak Isolate
GII.2.1976 None AY134748 Outbreak Isolate
GII.2.2002 None AB195225 Hu/GII/Ina/02/JP
GII.3.1999 None JQ743333 Outbreak Isolate
GII.4.1987 Ancestral AAK50355.1 Hu/NLV/GII/MD14512/1987/US
GII.4.1997 US95/96 JQ478407 Outbreak Isolate
GII.4.2002 Farmington Hills JQ478408 Outbreak Isolate
GII.4.2004 Hunter AAZ31376.2 Hu/GII.4/Hunter284E/04O/AU
GII.4.2005 None BAE98194.1 Hu/Sakai/04/179/2005/JP
GII.4.2006 Minerva/2006b JQ478409 Outbreak Isolate
GII.4.2009 Minerva/2006b ADD10375 Hu/GII.4/New_Orleans1805/2009/USA
GII.12.2010 None HQ401025 Hu/GII.12/HS207/2010/USA
doi:10.1371/journal.ppat.1002705.t001
Figure 1. EIA Reactivity of plasma collected from healthy
donors against norovirus VLPs. VLP-specific IgG titers in 63 plasma
samples collected in early 2009 were measured by EIA using a panel of
norovirus VLPs as antigen. Reciprocal ED50 dilutions (see Materials and
Methods) are shown. Highlighted in red is the plasma sample of the
donor NVB selected for the isolation of human mAbs. ED50 values
below 10 were scored as negative and assigned a value of 1. The line
shows the geometric mean value.
doi:10.1371/journal.ppat.1002705.g001
GII.4 Norovirus Human Monoclonal Antibodies
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ization and isolation of norovirus-specific mAbs. The NVB plasma
sample was tested again by EIA against a larger panel of norovirus
VLPs and shown to react with the entire panel of GII.4 VLPs
representing epidemic strains from 1987 to 2009 (Table 2 and
Figure S2). Plasma did not react with GI.1 VLPs. Plasma reactivity
to VLPs representing genogroup II strains outside the GII.4
genocluster was variable by strain. NVB plasma efficiently blocked
pig gastric mucin (PGM) binding of each of the GII.4 VLPs
(Figure 2). However, significantly less plasma was needed to block
GII.4.2006 binding to PGM (EC50 0.0353% plasma) than was
needed to block the other GII.4 VLPs binding to PGM (EC50
range 0.0673–0.1791% plasma), supporting an association be-
tween the donor plasma titers and the prevalence of global
circulating NoV strains. Having demonstrated antibody responses
to the complete GII.4 panel, memory B cells from this PBMC
donor were EBV-immortalized and seven anti-GII.4 mAbs were
isolated and characterized. Of note, all seven mAbs were isotype
IgG1, agreeing with previous observations of a predominantly Th1
mediated immune response to norovirus in challenged volunteers
(data not shown and [36,44]). None of the antibodies recognized
GI VLPs (data not shown and Table 2 and Figure S2). EIA
reactivity was limited to GII.4 strains for mAbs NVB 114, 97, 111,
43.9 and 71.4. Monoclonal Abs 37.10 and 61.3 extended reactivity
to include additional VLPs from GII.1, GII.2 and GII.12
genoclusters (Table 2 and Figure S2). The reactivity of mAbs
between GII.4 VLPs varied, but could be grouped into time-
related clusters for four of the seven human mAbs. The remaining
three mAbs demonstrated broad GII.4 reactivity.
Characterization of a human mAb specific for early GII.4
norovirus strains
Human mAb NVB 114 reacted by EIA and blockade assay
exclusively with GII.4.1987 and GII.4.1997 (Table 2, Figure 3,
and Figure S2). Significantly more antibody was needed to block
GII.4.1997-PGM binding (EC50 0.4152 mg/ml) than GII.4.1987-
PGM binding (EC50 0.3414 mg/ml) (Figure 3B) (p,0.05),
supporting the hypothesis that subtle antigenic differences exist
between these strains.
Table 2. NVB plasma and monoclonal antibody EIA reactivity to norovirus VLPs.
NVB Antibody Plasma 114 97 111 43.9 37.10 61.3 71.4
VLP
GI.1.1968 2 2 2 2 2 2 2 2
GI.1.2001 2 2 2 2 2 2 2 2
GII.1.1971 + 2 2 2 2 + + 2
GII.2.1976 2 2 2 2 2 + + 2
GII.2.2002 2 2 2 2 2 + + 2
GII.3.1999 2 2 2 2 2 + + 2
GII.12.2010 + 2 2 2 2 + + 2
GII.4.1987 + + 2 2 2 + + +
GII.4.1997 + + 2 2 2 + + +
GII.4.2002 + 2 2 2 2 + + +
GII.4.2004 + 2 + 2 2 + + +
GII.4.2005 + 2 + 2 2 + + +
GII.4.2006 + 2 + + + + + +
GII.4.2009 + 2 + 2 + + + +
+; mean optical density after background subtraction for VLP-coated wells was greater than three times the mean optical density for PBS-coated wells.
doi:10.1371/journal.ppat.1002705.t002
Figure 2. Characterization of donor NVB plasma blockade of
norovirus VLPs. Panel A: PGM binding blockade activity. Sigmoidal
curves were fit to the mean percent control binding calculated by
comparing the amount of VLP bound to PGM in the presence of
antibody pretreatment to the amount of VLP bound in the absence of
antibody pretreatment. Error bars represent the standard error of the
mean. Panel B: Mean EC50 (% plasma) for blockade of each VLP. * VLPs
with EC50 values significantly different from the EC50 for GII.4.2006.
doi:10.1371/journal.ppat.1002705.g002
GII.4 Norovirus Human Monoclonal Antibodies
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Characterization of a human mAb specific for
contemporary GII.4 norovirus strains
In contrast to the early strain GII.4 reactivity of NVB 114, EIA
of human mAb NVB 97 exclusively recognized VLPs of
contemporary circulating (2004–2009) GII.4 strains (Table 2 and
Figure S2); VLPs representing GII.4 strains circulating prior to
2004 were not recognized by NVB 97. Accordingly, the NVB 97
blocked VLP-PGM interaction of GII.4.2005, 2006 and 2009
VLPs (Figure 4). A comparable blockade assay for GII.4.2004 is
not available, as our strain doesn’t bind carbohydrate ligand under
our conditions of treatment [13,17,34]. However, under standard
conditions, the EC50 for GII.4.2006 (0.1195 mg/ml) was signifi-
cantly less than the EC50 of GII.4.2005 (0.1559 mg/ml) and
GII.4.2009 (0.1810 mg/ml) (Figure 4B) (p,0.05). These data are
consistent with the hypothesis that the contemporary 2009
Minerva variant may be diverging antigenically from its 2006
Minerva variant ancestral strain.
Characterization of human mAbs specific for Minerva
variant strains
The difference in blockade sensitivity of GII.4.2006 and
GII.4.2009 to NVB 97 provides the first evidence of subtle
antigenic divergence between two Minerva variants, each of which
caused widespread outbreaks globally [1]. This observation is
further supported by Human mAbs NVB 111 and NVB 43.9
reactivity profiles. By single-dilution EIA, NVB 111 specifically
reacted to 2006 but minimally with the 2009 variant of Minerva
and other tested VLPs (Table 2 and Figure S2). Accordingly, NVB
111 required 13-fold more antibody to block GII.4.2009-PGM
interaction (EC50 9.953 mg/ml) than it required to block
GII.4.2006-PGM interaction (EC50 0.7376 mg/ml) (Figure 5A
and B) (p,0.05). In comparison, NVB 43.9 specifically recognized
both the 2006 and 2009 Minerva variants by EIA (Table 2 and
Figure S2). The interaction of both variants with PGM ligand was
efficiently blocked by NVB 43.9 (Figure 5C and D). At relatively
low antibody concentrations, NVB 43.9 did significantly differen-
tiate GII.4.2006 from GII.4.2009 (EC50 0.1031 and 0.1739 mg/
ml, respectively). Combined, these three human mAbs (NVB 97,
111, and 43.9) indicate that GII.4.2006 and GII.4.2009 are
diverging from each other at the antigenic level, but that
significant 2006 blockade epitopes are still preserved, suggesting
that additional evolution is needed prior to the emergence of an
antigenically distinct, new pandemic strain.
Characterization of broadly-reactive human anti-GII.4 mAbs
NVB 114, 97, 111, and 43.9 recognize blockade epitopes that
are evolving over time (Figures 3–5). Three additional antibodies
recognize epitopes that are highly conserved over time. Human
mAbs NVB 37.10 and 61.3 exhibited broad GII reactivity,
detecting VLPs from GII.1, GII.2, GII.3 and GII.12 genoclusters
and the entire panel of time-ordered GII.4 (1987–2009) VLPs
(Table 2 and Figure S2). Despite broad EIA reactivity, NVB 37.10
Figure 3. Human mAb NVB 114 recognizes a blockade epitope
restricted to early GII.4 strains. Panel A: PGM binding blockade
activity. Sigmoidal curves were fit to the mean percent control binding
calculated by comparing the amount of VLP bound to PGM in the
presence of antibody pretreatment to the amount of VLP bound in the
absence of antibody pretreatment. Error bars represent the standard
error of the mean. Panel B: Mean EC50 (mg/ml) for blockade of each
VLP. * VLP with EC50 value significantly different from the EC50 for
GII.4.1987.
doi:10.1371/journal.ppat.1002705.g003
Figure 4. Human mAb NVB 97 recognizes a blockade epitope
restricted to contemporary GII.4 strains. Panel A: PGM binding
blockade activity. Sigmoidal curves were fit to the mean percent control
binding calculated by comparing the amount of VLP bound to PGM in
the presence of antibody pretreatment to the amount of VLP bound in
the absence of antibody pretreatment. Error bars represent the
standard error of the mean. Panel B: Mean EC50 (mg/ml) for blockade
of each VLP. * VLP with EC50 value significantly different from the EC50
for GII.4.2006.
doi:10.1371/journal.ppat.1002705.g004
GII.4 Norovirus Human Monoclonal Antibodies
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and 61.3 did not efficiently block VLP-PGM interactions for any
GII.4 VLP tested (Figures 6A and B). In contrast, human mAb
NVB 71.4 recognized the entire time-ordered GII.4 VLP panel
but was unreactive with any other GII VLPs (Table 2 and Figure
S2). Remarkably, NVB 71.4 blocked VLP-PGM interaction of
each of the GII.4 VLPs (Figure 6C). The blockade potential varied
between the VLPs. GII.4.2002 and GII.4.2006 had similar EC50
values (1.095 and 0.9233 mg/ml, respectively), while significantly
less antibody was needed for blockade of GII.4.1987 (EC50
0.4506 mg/ml) and GII.4.2009 (EC50 0.2716 mg/ml) and signif-
icantly more antibody was needed to block GII.4.1997 (EC50
13.73 mg/ml) and GII.4.2005 (EC50 3.544 mg/ml) (Figure 6D).
These three human mAbs indicate the existence of conserved
GII.4 epitopes over the past twenty-five years and across three
pandemic strains that could serve as targets for broad-based
vaccine design. Importantly, NVB 71.4 represents the first
potential, broad spectrum immune-therapeutic for any NoV.
Confirmation of mAb blockade phenotypes by
alternative approaches
In addition to VLP-PGM interaction blockade assay, human
mAbs were also tested for blockade of VLP-synthetic biotinylated
HBGA (Bi-HBGA) interaction and ability to block VLP hemag-
glutination of O+ RBCs. Regardless of substrate (PGM or Bi-
HBGA), the dose-response profiles for all blockade antibodies and
VLPs were similar (compare Figures 3–6 to Figure 7). Reflecting
valency differences in the number of potential binding sites of
HBGA in the two substrates, the EC50 values differed between
assays (compare Tables S1 and S2). NVB 114 blocked only
GII.4.1987 (EC50 0.1054 mg/ml) and GII.4.1997 (EC50
0.3275 mg/ml), with 1997 blockade requiring significantly more
mAb (p,0.05). NVB 97 blocked only GII.4.2005 (EC50
0.1835 mg/ml), 2006 (EC50 0.0668 mg/ml), and 2009 (EC50
0.1732 mg/ml) with blockade of GII.4.2005 and 2009 requiring
significantly more mAb than the blockade of GII.4.2006 (p,0.05).
NVB 111 and 43.9 blocked only GII.4.2006 (EC50 0.3324 and
0.05406 mg/ml, respectively) and 2009 (EC50 2.727 and
0.1140 mg/ml, respectively) with significantly more mAb needed
to block 2009 for both antibodies (p,0.05). Importantly, the broad
blockade phenotype of NVB 71.4 was reproduced in the Bi-
HBGA blockade assay. The EC50 value varied by VLP and
ranged from 0.0906 mg/ml for GII.4.1987 to 1.219 mg/ml for
GII.4.2005. Agreeing with the PGM assay, only GII.4.2002 (EC50
0.1679 mg/ml) and GII.4.2006 (EC50 0.2039 mg/ml) were
blocked similarly (p.0.05). NVB 37.10 and 61.3, the two mAbs
that did not block PGM interaction of any tested VLP, both
blocked GII.4.2009 interaction with synthetic Bi-HBGAs by at
least 50% (Figure 7E and F), although EC50 titers were relatively
high (EC50 0.9753 and 1.581 mg/ml for NVB 37.10 and 61.3,
respectively), compared to the amount of antibody needed to block
GII.4.2009 by the strain-specific mAbs (EC50 0.1140 and
0.1732 mg/ml for NVB 43.9 and 97). Repeated testing with
PGM as substrate did not replicate the findings with synthetic
carbohydrate substrates (Figure 6A and B).
An additional measurement of antibody blockade ability uses
RBCs as the VLP binding substrate. Previous work has
demonstrated that Norwalk virus VLPs hemagglutinate (HA) O+
RBCs, that this interaction can be disrupted by antibodies found in
polyclonal serum (hemagglutination inhibition; HAI), and that the
Figure 5. Human mAbs NVB 111 and 43.9 recognize a blockade epitope restricted to Minerva variants. Panel A (NVB 111) and C
(NVB 43.9): PGM binding blockade activity. Sigmoidal curves were fit to the mean percent control binding calculated by comparing the amount of
VLP bound to PGM in the presence of antibody pretreatment to the amount of VLP bound in the absence of antibody pretreatment. Error bars
represent the standard error of the mean. Panels B (NVB 111) and D (NVB 43.9): Mean EC50 (mg/ml) for blockade of each VLP. * VLP with EC50
value significantly different from the EC50 for GII.4.2006.
doi:10.1371/journal.ppat.1002705.g005
GII.4 Norovirus Human Monoclonal Antibodies
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HAI titer of serum correlates with antibody blockade of VLP-Bi-
HBGA interaction [38,39,45]. To determine if these findings
could be extended to study GII.4 VLP blockade, we first tested
each GII.4 VLP for hemagglutination ability. In contrast to
Norwalk VLPs, which demonstrated robust HA activity, VLPs of
GII.4.1987, 1997, and 2009 did not reproducibly HA O+ RBCs
(data not shown). GII.4.2002, 2005 and 2006 did HA O+ RBCs,
and VLP HA was inhibited by NVB plasma (HAI 0.01% plasma
for GII.4.2002 and 2005 and 0.001% plasma for GII.4.2006)
(Table S3). Neither NVB plasma nor any of the mAbs inhibited
Norwalk virus VLP HA. In agreement with the other two blockade
assays, GII.4.2006 VLP HA of O+ RBCs was blocked by NVB 97
(HAI 0.07 mg/ml), 111 (HAI 0.5 mg/ml), and 43.9 (HAI 0.04 mg/
ml) while HA of O+ RBCs by GII.4.2002 was unaffected by these
mAbs at 0.5 mg/ml. NVB 97 also inhibited GII.4.2005 HA (HAI
0.13 mg/ml) but not GII.4.2002. The HAI profile of the cross-
reactive mAbs had a weaker correlation with the blockade assays.
NVB 71.4 and 37.10 each inhibited HA of GII.4.2005 (HAI 0.5
and 0.25 mg/ml) and 2006 (HAI 0.13 and 0.25 mg/ml). NBV 61.3
only inhibited HA of GII.4.2002 at 0.25 mg/ml.
Macro scale evaluation of mAb epitopes
Our previous work with mouse-derived anti-norovirus mAbs
suggested that blockade epitopes are conformation dependent
[17,34]. To test the effect of protein conformation of human mAb
binding, we used both Western blot and EIA analysis to compare
antibody binding to GII.4.2006 VLPs and P proteins. P proteins of
GII.4.2006 are composed of the C-terminal portion of the major
capsid protein (amino acids 221–531) [21]. Expression of the P
protein in E. coli results in small particle formation estimated to
consist of 12 P dimers that reportedly maintains VLP character-
istics in carbohydrate and antibody binding studies [46,47]. None
of the human anti-GII.4 mAbs recognized either the denatured
VLP or P protein by Western blot analysis, suggesting that the
epitopes for these antibodies are conformation dependent (data
not shown). Surprisingly, only half of the mAbs that recognized
GII.4.2006 VLP (Figure 8A) by EIA also recognized GII.4.2006 P
protein by EIA (Figure 8B). NVB 71.4 and 61.3 extended their
broad reactivity to P proteins, whereas NVB 37.10 did not,
indicating that a minimum of three GII.4 cross-reactive epitopes
must exist. NVB 97 also detected P protein by EIA. Neither of the
Minerva variant mAbs recognized P protein even at protein
concentrations 8-fold above standard EIA conditions (1 mg/ml
coating protein). Further, all seven mAbs detected increasing
concentrations of VLP in a linear dose response with signals
saturating at 4 mg/ml of VLP when the mAb concentration was
held at 1 mg/ml, which is our standard EIA antibody titer
(Figure 8A). Antibody reactivity to the P protein saturated at a
Figure 6. Human mAbs NVB 37.10, 61.3 and 71.4 recognize a conserved epitope. PGM binding blockade activity of NVB 37.10 (Panel A),
NVB 61.3 (Panel B) and NVB 71.4 (Panel C). Sigmoidal curves were fit to the mean percent control binding calculated by comparing the amount of
VLP bound to PGM in the presence of antibody pretreatment to the amount of VLP bound in the absence of antibody pretreatment. Error bars
represent the standard error of the mean. Panel D: Mean EC50 (mg/ml) for blockade of each VLP by NVB 71.4. * VLPs with EC50 value significantly
different from the EC50 for GII.4.2006.
doi:10.1371/journal.ppat.1002705.g006
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lower protein concentration than VLP and at optical densities
below the linear range of the assay (compare Figure 8A and 8B),
suggesting that even among the mAbs that bind to P proteins
conformation-based epitopes may be limited in a way not observed
with VLPs. These data suggest two important points. First, some of
the mAb epitopes are highly sensitive to conformation, and
secondly, that the principle P protein conformation is not identical
to VLPs at least for some critical blockade epitopes.
Predicting putative GII.4 evolving antibody epitopes
The evolution of the GII.4 noroviruses was assessed over a 36-
year period of time by comparing strains from 1974 to 2010. In
comparing these sequences, sites of variation in the P2 subdomain
were noted, and these sites were mapped onto the crystal structure
of the P-domain dimer for the 1997 strain VA387. Surface-
exposed sites of variation were then examined to determine which
residues may be close enough to constitute a single epitope, and
five epitopes were predicted based upon this variation (Figure 9A,
and [40]).
Epitope A encodes significant amino acid changes over time and
has also been demonstrated to be an evolving GII.4 blockade
epitope using mouse mAbs (Figure 9A, 9B and [43]). Epitope A is
conformational and is located on the top of the capsid proximal to
the HBGA binding pocket. Six variable sites were close to each
other in the region of this putative epitope, suggesting that these
residues may work in concert to change the local structure of
Epitope A. The variable, surface-exposed residues include
positions 294, 296–298, 368 and 372. Of note, Epitope A is
continuing to evolve in extant strains, whereby the amino acid at
position 294 seems to vary extensively in strains from 2008–2010
(amino acid replacements P294A, P294S and P294T have been
observed at this position). Epitope B was predicted based upon two
variable residues at positions 333 and 382. While these residues
are buried in the dimer interface between two chains, the patterns
of variation at these sites suggest that they play an important role
in the evolution of novel strains, perhaps by evolving replacements
that allow the more surface exposed residues in other surface
exposed epitopes to dramatically change the physiochemical
properties of the amino acid replacements. Residues 340 and
376 make up the variable residues of putative Epitope C. This
putative conformation dependent epitope is on the surface and
lateral edge of the capsid and is directly proximal to the HBGA
binding pocket, suggesting that this epitope may play a role in
receptor switching along with Epitope D. Epitope D is comprised
Figure 7. Blockade of Bi-HBGAs by Hu mAbs. Bi-HBGA binding blockade activity of NVB 114 (Panel A), NVB 97 (Panel B), NVB 111 (Panel C),
NBV 43.9 (Panel D), NVB 37.10 (Panel E), NVB 61.3 (Panel F) and NVB 71.4 (Panel G). Sigmoidal curves were fit to the mean percent control binding
calculated by comparing the amount of VLP bound to Bi-HBGA in the presence of antibody pretreatment to the amount of VLP bound in the absence
of antibody pretreatment. Error bars represent the standard error of the mean. EC50 values are reported in Table S2.
doi:10.1371/journal.ppat.1002705.g007
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of three variable residues from positions 393–395. In the first
reported crystal structure for the GII.4 noroviruses, this region was
reported to be a secondary HBGA binding site [16]. However, the
location of this epitope on the surface of the capsid, directly
proximal to the HBGA binding site, suggests that it likely plays a
role in both receptor switching and in escape from herd immunity
and perhaps both, simultaneously [13,21,40,43]. Epitope D is
close enough to the HBGA binding pocket to contribute to or
inhibit carbohydrate binding, and yet variable enough to suggest
that it is targeted by the immune response. Putative Epitope E is
comprised of variable residues 407, 412 and 413, which are
surface exposed regions lateral to the HBGA binding pockets and
the other epitopes. These residues vary with every major epidemic
strain after 2002, suggesting that it is a hot spot for the emergence
of immunologically novel GII.4 strains. Epitope E is a GII.4.2002
blockade antibody epitope [17]. This putative epitope is lateral to
the HBGA binding pockets indicating that antibodies are targeting
interior regions below the capsid surface, which suggests that other
epitopes may be present in the P1 subdomain. A few variable
residues do not necessarily identify the boundaries of a putative
epitope. Moreover, it is nearly impossible to predict the surface
area of a putative epitope by sequence analysis alone. Therefore,
we expanded the putative epitopes to include residues within 8 A˚
of the variable sites from which the epitopes were predicted
(Figure 9B).
Mapping of GII.4 blockade epitopes
The described mAbs indicate at least five unique or overlapping
GII.4 blockade epitopes with different specificities: 1) early GII.4
strain specific, 2) contemporary GII.4 strain specific, 3) Minerva-
variant strain specific, 4) genogroup II strain specific, and 5) GII.4
strain specific. Using capsid sequences as a guide, mutant VLPs
were designed to contain chimeric combinations of the predicted
evolving GII.4 epitopes (Figure 10). Each predicted epitope was
exchanged between the 1987 and 2006 parental strain VLPs. For
example, Epitope A exchange mutant VLP GII.4.1987/2006A
retains the backbone sequence of GII.4.1987 but Epitope A has
been replaced with Epitope A from GII.4.2006. Whereas,
GII.4.2006/1987A retains the backbone sequence of GII.4.2006,
but Epitope A has been replaced with Epitope A from GII.4.1987.
All epitope exchange VLPs were morphologically intact by
electron microscopy visualization and retained the ability to bind
PGM (Figure 10A and B, [43]), confirming chimeric VLP
structural integrity.
Epitope mutant VLPs were compared to wild type strain VLPs
for reactivity to the donor plasma sample. Consistent with high
EIA reactivity to GII.4.1987 and 2006 VLPs (Table 2 and Figure
S2), donor plasma reacted across the panel of epitope-exchange
mutant VLPs (Figure 10B). Donor plasma was able to block each
epitope-exchanged VLP binding to PGM (Figure 11A and C).
Exchange of all of the epitopes, except Epitope D into either
backbone and GII.4.1987 C into GII.4.2006 resulted in signifi-
cantly different EC50 values compared to the parental strains
(Figure 11B, 11D, and Table S4) (p,0.05). Only the exchange of
Epitope A between the backbones resulted in an exchanged
blockade phenotype, as observed with epitope-specific mAbs [43].
Exchange of Epitope A between the two parental backbones
resulted in a chimeric VLP (GII.4.1987/2006A) that was blocked
with significantly less plasma than the parental GII.4.1987 (EC50
0.0167 mg/ml compared to 0.0673 mg/ml) (p,0.05) and a
chimeric VLP (GII.4.2006/1987A) that was blocked with signif-
Figure 8. EIA Reactivity of mAbs to GII.4.2006 VLPs and P
proteins. Increasing concentrations of GII.4.2006 VLP (Panel A) or P
protein (Panel B) were assayed for reactivity to the hu mAbs by EIA.
Arrow indicates 1 mg/ml, the concentration of GII.4.2006 VLP scored as
postive by EIA (Figure S2 and Table 2). Bars are SEM.
doi:10.1371/journal.ppat.1002705.g008
Figure 9. Predicted GII.4 norovirus evolving blockade epi-
topes. Bioinformatic approaches predicted five antibody epitopes on
the surface of GII.4 noroviruses that appeared to be evolving over time
and to correlate with the emergence of new GII.4 outbreak strains.
Panel A: Amino acid variation of Epitopes A–E by GII.4 strain. Panel B:
Predicted epitopes were expanded to include interacting amino acids
within 8A. Epitope A (grey), Epitope B (blue), Epitope C (green), Epitope
D (black), Epitope E (teal) and HBGA binding sites (magenta) mapped
onto the P domain dimer of GII.4.2002.
doi:10.1371/journal.ppat.1002705.g009
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icantly more plasma than the GII.4.2006 parent (EC50
0.2770 mg/ml compared to 0.0353 mg/ml) (P,0.05). In compar-
ison, exchange of Epitope E between backbones resulted in
chimeric VLPs that required significantly more antibody for
blockade then either parental VLP (GII.4.1987/2006E; EC50
0.2025 mg/ml and GII.4.2006/1987E 0.0991 mg/ml) (Figure 11A–
D and Table S4) (p,0.05). In this individual, these data suggest
that Epitope A may be an important evolving GII.4 neutralization
epitope as the blockade response is significant enough to be
detected in the polyclonal antibody response.
Agreeing with the assumption that epitope-exchange mutants
are unlikely to identify epitopes of cross-reactive mAbs, NVB
37.10, 61.3 and 71.4 reacted with the entire panel of chimeric
VLPs by EIA (Figure 10B). In contrast, each of the strain-specific
mAbs displayed differential EIA reactivity to exchanged epitopes
A and D. NVB 114, 111 and 43.9 each recognized Epitope A. For
NVB 114, exchange of Epitope A between the 1987 and 2006
backbones resulted in loss of antibody binding to and blockade of
GII.4.1987/2006A (no blockade at 2 mg/ml) without gain of
binding to GII.4.2006/1987A (Figures 12A, 10B and Table S4).
Exchange of the other GII.4.1987 epitopes did not eliminate NVB
114 blockade potential (Figure 12A and B). Further, exchange of
Epitope A between the 1987 and 2006 backbones resulted in loss
of antibody binding to and blockade of GII.4.2006/1987A and
gain of antibody binding to GII.4.1987/2006A for both NVB 43.9
and 111 (Figures 12C–F, 10B and Table S4). NVB 111 needed
significantly more antibody to block GII.4.1987/2006A compared
to GII.4.2006 (EC50 1.152 compared to 0.7376 mg/ml) (p,0.05)
while NVB 43.9 needed slightly less antibody to block GII.4.1987/
2006A compared to GII.4.2006 (EC50 0.0366 compared to
0.1031 mg/ml) (p,0.05). For both antibodies GII.4.2006/1987A
was not blocked at 2 mg/ml. These data suggest that Epitope A
defines a GII.4 evolving neutralization epitope for the human
antibodies.
Similarly, the exchange of Epitope D of GII.4.2006 with
Epitope D of 1987 (GII.4.2006/1987D) ablated binding of and
blockade by NVB 97. Conversely, exchange of Epitope D of
GII.4.1987 with Epitope D of 2006 (GII.4.1987/2006D) conferred
a significant amount of binding to GII.4.1987/2006D and even
blockade activity of the VLP binding to PGM (Figure 13A and B).
Binding was not restored to wild type levels as the EC50 of
GII.4.1987/2006D was 0.6349 mg/ml, significantly higher than
the blockade EC50 for GII.4.2006 –PGM (0.1195 mg/ml)
(Figure 13B and Table S4) (p,0.05). Both EIA and blockade
data clearly indicate that Epitope D is critical for the binding of
NVB 97 and suggest that amino acids 393–395 are important
components of a GII.4 evolving blockade epitope in addition to
modulating VLP-carbohydrate ligand binding [13,21]. Interest-
ingly, Epitope D has a single amino acid change in GII.4.2004,
explaining the highly conserved binding and blockade responses
noted across GII.4.2005 to 2009 VLPs, while ancestral strains
display significant antigenic variation across these residues.
Together, these data map the GII.4 evolving blockade epitopes
recognized by each of the four strain-exclusive human mAbs
described in this study (Figure 14).
Discussion
Noroviruses are recognized as a leading cause of viral food-
borne gastroenteritis. With the successful vaccination program
being developed against rotavirus, focus is shifting to norovirus as
the primary causative agent of severe childhood diarrhea resulting
Figure 10. Characterization of Epitope A through E exchanged VLPs. Panel A: Electron microscopy visualization of negative-stained
epitope-exchanged VLPs. Panel B: Antibody and PGM binding phenotypes of epitope-exchanged VLPs.
doi:10.1371/journal.ppat.1002705.g010
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in a yearly estimate of 1.1 million episodes of pediatric
gastroenteritis in developed nations and 218,000 deaths in
developing nations [9]. The elderly and immunocompromised
also suffer sometimes life-threatening or chronic long-term
norovirus diarrheal disease characterized by malnutrition and
dehydration [48]. In some HIV infected patients, chronic
norovirus diarrheal disease is associated with persistent norovirus
infection [49]. The economic disease burden of a norovirus
outbreak within a care facility has been estimated at over $657,000
for a single event [50]. These statistics emphasize the critical need
for a norovirus vaccine. Although recent reports strongly support
the development and use of an efficacious norovirus vaccine in
humans [38,51], a primary obstacle to a successful vaccine is the
lack of a definitive correlate to protection coupled with the
extreme antigenic variation across the many norovirus strains. In
fact, the existence of long-term protective immunity to norovirus
infection remains controversial within the field [52]. Human
challenge studies conducted before molecular diagnostics of
infection and refined immune response assays had indicated that
some volunteers could be reinfected with the same norovirus
strain, suggesting that norovirus infection did not induce long-term
protection [53]. However, recent reports identifying immune
responses in norovirus-challenged but uninfected volunteers
[44,54] have necessitated qualification of these early observations
to acknowledge that the findings may be compromised by assay
limitations and/or the overwhelming challenge dose in compar-
ison to the very low norovirus infectious dose [44,54]. Clearly
defining the relationships between pre-exposure history, blockade
antibody responses, T cell immunity, virus evolution, and the
components of protective immunity represent key challenges for
future vaccine and therapeutic design.
In addition to the clinical applications of therapy and diagnosis,
monoclonal antibodies have also proven to be superior tools for
studying viral antigenicity, evolution, and for the treatment of
acute viral disease in humans [13,34,55,56]. Characterization of
neutralizing mAb escape-mutants has been fundamental to
identifying epitopes associated with virus receptor usage, patho-
genesis, and fitness [57–59]. In this manuscript, we isolated and
characterized the first human mAbs against noroviruses, derived
from a healthy donor whose pre-exposure history was unknown.
The number of unique GII.4 human monoclonal antibodies in this
patient accurately reflects the high prevalence of GII.4 norovirus
Figure 11. Characterization of donor NVB plasma reactivity to engineered epitope-exchanged VLPs. PGM binding blockade activity
against GII.4.1987 (Panel A) and GII.4.2006 (Panel C) Epitope A–E chimeric VLPs. Sigmoidal curves were fit to the mean percent control binding
calculated by comparing the amount of VLP bound to PGM in the presence of antibody pretreatment to the amount of VLP bound in the absence of
antibody pretreatment. Error bars represent the standard error of the mean. Mean EC50 (% plasma) for blockade of each GII.4.1987 (Panel B) and
GII.4.2006 (Panel D) epitope-exchanged VLP. * VLPs with EC50 values significantly different from the EC50 for each parental VLP.
doi:10.1371/journal.ppat.1002705.g011
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infection seen in human populations over the past 25 years.
Moreover, distinct antibody cross reactivity patterns support the
hypothesis that the GII.4 genotype is undergoing antigenic
variation which not only correlates with loss of antibody blockade
activity and emergence of new epidemic norovirus strains, but also
changing carbohydrate ligand binding patterns over time.
Importantly, antibody-mediated antigenic drift of GII.4 strains
coupled with both mucosal IgA and T cell responses in challenged
but uninfected volunteers strongly support the existence of long-
term protective immunity against norovirus strains. In fact, the
unique antibody reactivity patterns characterized herein are most
likely explained as an archeological immune record of successive
Figure 12. Epitope A comprises an evolving GII.4 blockade epitope recognized by NVB 114, 111 and 43.9. Hu mAb PGM binding
blockade activity against GII.4.1987 epitope-exchanged VLPs for NVB 114 (Panel A) and Epitope A exchanged between GII.4.1987 and GII.4.2006
(Panels C and E). Sigmoidal curves were fit to the mean percent control binding calculated by comparing the amount of VLP bound to PGM in the
presence of antibody pretreatment to the amount of VLP bound in the absence of antibody pretreatment. Error bars represent the standard error of
the mean. Mean EC50 for blockade of each GII.4.1987 exchange epitope (Panel B) and Epitope A exchange VLPs (Panel D and F). * VLPs with EC50
values significantly different from the EC50 for each parental VLP.
doi:10.1371/journal.ppat.1002705.g012
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waves of contemporary GII.4 infections in this individual over
time, implying that successful vaccine design is possible, as
previously proposed by our group and others [37,44,54].
Previously, we have identified two immunological responses
associated with protection from infection in norovirus-challenged
volunteers. An early (day 1–3) post-exposure salivary IgA response
in genetically susceptible volunteers correlated with protection
from Norwalk virus infection [54] and an early Th1 response
correlated with protection from Snow Mountain virus infection
[44]. Historically, the role of IgG in norovirus protection has been
unclear. By adulthood, .90% of the population [48] is positive for
anti-norovirus IgG, and norovirus strains within a genogroup
share a high degree of antigenic cross-reactivity as measured by
EIA [44,60]. These facts likely skew functional interpretations of
the role of serum IgG titers on susceptibility to infection and/or
infection outcomes. Although carbohydrate ligand blockade
antibody responses have been suggested as correlates of protective
immunity [13,35,36], it wasn’t until recently that these blockade
responses were correlated definitively with protection from clinical
disease and infection [10,38]. Importantly, our surrogate neutral-
ization assay is specific enough to differentiate GII.4 norovirus
strains too similar to be distinguished by EIA but different at key
antigenic sites. While human re-challenge studies using the same
viral inoculum are necessary to confirm an association between a
blockade IgG response and protection from repeat norovirus
infection, our findings support the clinical relevance of the antibody
blockade assay as a correlate of protective immunity [38].
Monoclonal antibodies coupled with the blockade assay are
powerful tools for elucidating the antigenic relationship between
GII.4 strains. While mouse mAbs provide insight into GII.4
antigenic structure, data in this manuscript argues that human
mAbs offer considerable advantages, including: a) immunologic
record of B-cell immunity following repeat GII.4 infection, b)
relationships between antibody blockade responses and antigenic
variation, c) relationships between immune selection and carbo-
hydrate ligand reactivity, d) relationships between early infection
and downstream immunity, and e) epitope mapping. We focused
on anti-GII.4 mAbs because of the clinical relevance of the GII.4
strains. One key finding is a direct relationship between anti-GII.4
human mAb carbohydrate ligand blockade responses and the
emergence of new GII.4 epidemic strains. While similar findings
were also observed for mouse anti-GII.4 mAbs, key differences
were observed including the presence of human mAbs that
distinguished between the 1997 and the 2002 VLPs, definitively
delineating an antigenic break between the pandemic 1997 (US
95/96) and 2002 (Farmington Hills) strains. Equally important is
the observation that different GII.4 antibody-blockade epitopes
change with different epidemic strains. The blockade epitope
recognized by NVB 114 (an early version of Epitope A) is exclusive
for the early GII.4 strains, and doesn’t recognize 2002 or other
Figure 13. Amino acids 393–395 comprise a blockade epitope
for contemporary GII.4 strains recognized by NVB 97. Panel A:
NVB 97 PGM binding blockade activity against Epitope D exchange
VLPs. Sigmoidal curves were fit to the mean percent control binding
calculated by comparing the amount of VLP bound to PGM in the
presence of antibody pretreatment to the amount of VLP bound in the
absence of antibody pretreatment. Error bars represent the standard
error of the mean. Panel B: Mean EC50 for blockade of each blocked
VLP. * indicates VLPs with significantly different EC50 compared
GII.4.2006.
doi:10.1371/journal.ppat.1002705.g013
Figure 14. Summary of exchange mutant VLPs containing blockade Epitopes A and D and the reactivity pattern of the human
mAbs that recognize these epitopes.
doi:10.1371/journal.ppat.1002705.g014
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contemporary variant GII.4 VLPs (Figure 3). Given the lack of
cross reactivity with later strains, the most likely explanation is that
NVB 114 was derived from a long-term memory plasma cell that
had been elicited some 12–22 years earlier. In support of this idea,
examination of human monoclonal antibodies against 1918 H1N1
influenza also identified antibody variants that recognized
ancestral or contemporary isolates [61]. The exclusive blockade
reactivity of NVB 114 with GII.4.1987 and 1997 supports
potential long-term protective immunity. Further, NVB 114 is
the first antibody identified to clearly demonstrate antigenic
difference between GII.4.1987 and GII.4.1997, suggesting that
antigenic variation may have subtly contributed to the emergence
of the GII.4 US 95/96 pandemic strain from ancestral strains.
Human monoclonal antibodies clearly identified two evolving
epitopes on the surface of the GII.4 VLP. Epitopes A and D were
both confirmed as evolving GII.4 antibody blockade epitopes
using chimeric VLPs containing a mixture of epitopes derived
from early or contemporary strains. We recognize that Epitopes A
and D have not been structurally defined as epitopes, supporting
the need for structural studies to define the exact mAb binding site
on the VLPs. Moreover, we focused on discrete regions of varying
residues and all of the residues within 8 A˚ (representing
approximately 201 A˚2) to the primary sites that may be influenced
directly by an amino acid replacement (Figure 9B). However, Ab
binding sites have been reported to be much larger (700–800 A˚2),
suggesting that the epitopes that we have predicted may actually
work in concert to form larger Ab recognition sites. By expanding
the putative epitopes, we identified other residues that were less
variable; however, the exact role that these varying residues play in
evolution is less clear. In some cases variation may be required to
encode changes that are necessary for the replacement at a
primary site. In addition, all of our structural analyses have been
conducted using models of the P dimer, representing about 1/90th
of the VLP structural surface. Interactions between the epitopes in
the context of the superstructure have not been determined.
Therefore, these observations indicate that the complex nature of
the NoV Ab epitope requires further research to define the specific
boundaries and residues that regulate Ab binding.
The prediction of five putative epitopes allowed us to gain
several important insights into GII.4 norovirus evolution: 1)
Discrete sites of variation occur on the GII.4 norovirus capsid,
either directly on the surface or lateral to the HBGA binding sites;
2) Secondary variable sites are within 8 A˚ of the primary variable
sites, and these secondary sites could also contribute to epitope
remodeling; 3) Many of the putative expanded epitopes overlap,
suggesting that two or more highly variable epitopes may work in
concert to escape from an antibody response; 4) Putative epitopes
that are buried may exert an effect on the structure by altering the
interior fold space, allowing unconventional replacements to be
tolerated; 5) An underlying amino acid network likely preserves
the functional core of the capsid proteins by regulating the variable
residues above them; and 6) Escape and HBGA binding may be
intimately linked via the underlying regulatory network of amino
acids that preserve the functional integrity of the capsid core.
Epitope A, which likely includes varying amino acid residues
294, 296–298 and 368 and 372 and potentially other undefined
nearby residues, has been mapped as a blockade epitope in both
GII.4.1987 and GII.4.2006 Minerva variants. Importantly, the
antibodies that recognize Epitope A in GII.4.1987 do not bind
GII.4.2006 and the antibodies that recognize Epitope A in
GII.4.2006 did not recognize GII.4.1987 (Figures 3, 5, 12 and
[43]). These data support the idea that unique memory B cells
were elicited as a consequence of unique exposure events, most
likely years apart in this individual. Further, the significant
difference in EC50 values between the 2006 and 2009 Minerva
variants for NVB 111 and 43.9 (Figure 5) suggests that Epitope A
continues to evolve and the epidemic 2009 stain is still diverging
from the pandemic 2006 strain at this site, most likely as a
consequence of long-term antibody selection. GII.4.2006 and
2009 differ at positions 294, 368 and 372 within Epitope A
(Figure 9A). At this time it is unclear how many and which amino
acids in Epitope A are needed to mediate an escape mutant
phenotype that is completely resistant to GII.4.2006 antibody
blockade. However, it is clear that Epitope A varies, and that the
site is conserved as a major target for blockade antibody response
between 1987 and 2009. Although correlative, comparisons of
Epitope A variation along with residues that are proximal to those
that appear to be evolving over time suggest that changes at
positions 292, 293, 294, 295, 296, 297, 298, 300, 365, 367, 368
and 372 might contribute to an escape phenotype, with residues
294, 296, 297, 298, 300, 368 and 372 playing direct roles in this
variation (Figure 9). However, the minor replacements at other
positions are likely essential for remodeling the local structural
neighborhood such that more profound changes can be tolerated.
Supporting the sensitivity of epitopes to the local environment,
mAbs that recognized Epitope A differentiated between
GII.4.2006 VLPs and GII.4.2006 P dimers. P protein (P dimer)
is a dimeric, truncated form of the major capsid protein composed
of residues 214–539 [62]. P-dimers have been widely used to
determine the crystallographic structure of NoV-HBGA interac-
tions and are considered accurate reflections of the VLP surface
topology [16,21,63]. P –particles can assemble as higher ordered
structures composed of varying copies of the P dimer [46,64].
These subviral particles are reported to have similar characteristics
to VLPs [62,65–67] and have been proposed as a candidate
vaccine platforms [68]. To our knowledge, this is the first
immunologic characterization of P-dimers vs. VLPs using mono-
clonal antibodies derived from human infections. Here, P-dimers
derived from GII.4.2006 lost binding of mAbs NVB 111 and 43.9,
the mAbs that recognize Epitope A in GII.4.2006. P dimer
binding to the Epitope D binding mAb NVB 97 and the broadly
cross-blockade mAb NVB 71.4 were retained. Recently, P-particle
vaccines were shown to be less robust at inducing strong blockade
responses, as compared with intact VLP [69], perhaps because of
the loss of blockade Epitope A in this higher ordered structure.
While speculative, it is recognized that virions ‘‘breathe’’
suggesting that the possibility that P-dimers and P-particles may
become ‘‘locked’’ in a slightly less immunologically reactive state
that affects some but not all blockade epitopes on the virion surface
[70,71]. These data absolutely underscore the critical importance
of determining the structures of several of these human mAbs with
their appropriate GII.4 VLP epitopes by either cryoEM or
crystallography, for informing targeted mutagenesis to identify the
role of key residues in regulating antigenicity and antibody escape.
Epitope D is a conformational epitope comprised of varying
amino acids 393–395 and likely other nearby residues that are less
clearly defined; however, additional mapping and crystallographic
studies will be needed to clarify this epitope structure. With the
emergence of the pandemic GII.4.2004 Hunter strain, Epitope D
elicited robust antibody blockade responses as typified by NVB 97.
These observations suggest that Epitope D has been relatively
static since 2004 and may be a good target for vaccine
development. Although the blockade epitope is conserved post
2002, comparison of EC50 titers suggests that the antibody’s
highest efficacy is against GII.4.2006, as all other VLPs have
significantly less robust EC50 values (Figure 4). Previously, these
residues have been implicated in regulating norovirus VLP-
carbohydrate ligand binding interactions [13,21,43]. The identi-
GII.4 Norovirus Human Monoclonal Antibodies
PLoS Pathogens | www.plospathogens.org 14 May 2012 | Volume 8 | Issue 5 | e1002705
fication of Epitope D as a human antibody blockade epitope that
changes over time provides direct support for our previous
hypothesis that escape from protective herd immunity may drive
changes in carbohydrate ligand binding affinities over time and
potential retargeting of virus infection in different human
populations [13,40].
These data indicate that like influenza, a successful norovirus
vaccine regimen will require periodic population sampling to
identify future strains for inclusion into the next year’s vaccine
formulation not unlike the strategy employed by the Influenza
Virus Global Surveillance Program. Norovirus population sam-
pling has already begun as monitoring systems for detection of
NoV infections have been established in the United States,
Europe, and Japan. Identification of GII.4 evolving antigenic
epitopes furthers our understanding of norovirus pathogenesis and
provides target epitopes that may be useful for surveillance and
prediction of new strain emergence. Identification of GII.4
conserved epitopes also informs diagnostic and potential thera-
peutic reagent development and design. Monoclonal antibodies
NVB 37.10, 61.3 and 71.4 all recognize epitopes conserved among
the GII.4 strains from 1987 through 2009. NVB 37.10 and 61.3
have enhanced GII VLP recognition, binding not only GII.4 VLPs
but also other GII VLPs, but are unable to block VLP-PGM
interaction. The high conservation of the NVB 37.10 and 61.3
epitopes suggest that these epitopes are highly resistant to antigenic
variation within the GII strains, making these mAbs potentially
valuable diagnostic reagents as GII strains cause up to 95% of
norovirus outbreaks [27,72]. The unidentified epitope for NVB
71.4 is clearly different from the epitopes recognized by NVB
37.10 and 61.3 and is conserved throughout the GII.4 strains.
NVB 71.4 did not recognize any non-GII.4 VLPs but, important-
ly, it exhibited blockade activity for the entire panel of time-
ordered GII.4 VLPs with PGM and Bi-HBGAs. Emphasizing the
difference between the two quantitative blockade assays and the
qualitative HAI assay, GII.4.2002 HA was not inhibited by NVB
71.4. Noting that blockade assays are not true measurements of
neutralization, NVB 71.4 has potential as a therapeutic reagent
based on its broad GII.4 blockade potential and the fact that it is
by nature a human antibody. Clearly, the effectiveness of NVB
71.4 at preventing or treating illness can only be determined
empirically. Although one of the blockade-epitope specific mAbs
with lower EC50 values/steeper Hill constants may be more
effective at select strain neutralization, the breadth of strains
neutralized is likely to be limited for these mAbs. There are a
number of viral diseases currently being treated with mAbs
including RSV, CMV and enterovirus; however, only the anti-
RSV humanized mAb palivizumab has FDA approval for
prophylactic use in humans [73,74]. In outbreak settings or in
chronically infected patients, an anti-NoV mAb that could be
delivered before symptoms begin and protect from illness could be
very useful in care facilities, the military and the cruise industry.
Given the acute clinical disease window, it is less likely that
therapeutic antibodies will provide relief in those individuals
experiencing acute infections, however, therapeutic antibodies
may offer opportunities for ameliorating symptomatic disease in
chronic infections. The discovery of broadly cross reactive and
cross blockade human GII.4 mAbs dictates the need for a new
approach to map epitopes. Our current experimental approach
was designed to identify GII.4 epitopes that change over time and
provide insight into broadly conserved epitope locations. Because
the identification of the epitopes recognized by NVB 37.10, 61.3,
and 71.4 has important implications for successful vaccine design,
new panels of mutated VLPs and other approaches will be needed
to characterize these epitopes in the future.
GII.4 NoVs are significant human pathogens that cause
considerable morbidity and mortality, worldwide. The develop-
ment of mouse mAbs to different time-ordered GII.4 VLPs has
greatly facilitated progress towards understanding the complex
antigenic relationships between these strains by clearly demon-
strating antigenic variation over time and epidemic strain [34].
Here we have expanded these observations using human anti-
GII.4 mAbs isolated from a healthy adult donor, who has likely
experienced multiple norovirus infections throughout his/her
lifetime. The identification of highly significant, varying antigenic
epitopes that influence VLP-carbohydrate ligand interaction
provides important new insights into vaccine design and the
development of therapeutics that target norovirus virions. For
example, these antibodies represent the first anti-norovirus human
mAbs to be characterized, and they confirm findings from studies
using mouse mAbs supporting antigenic drift and its linkage with
varying carbohydrate ligand binding profiles within the GII.4
noroviruses. Further, we have demonstrated that the GII.4 NoV
varying epitopes can be exchanged between time-ordered VLPs,
providing a robust platform for expanding the antigenic and
blockade cross reactivity of future vaccine candidates. Using this
approach, we have identified two surface-exposed antibody
blockade epitopes that vary over time and were differentially
recognized by four of the seven human mAbs. We also identified
three antibodies which recognize either overlapping or three
unique highly conserved epitopes within the GII.4 VLP. These
data continue to support the hypothesis that norovirus long-term
protective immune responses are elicited following acute infection,
a concept essential for effective vaccine design. We anticipate that
a full understanding of the varying antigenic and blockade
epitopes of GII.4 NoVs may not only help to predict the
emergence of new epidemic strains but simultaneously identify
key reformulations in vaccine design that will protect public health
against contemporary and emerging epidemic strains in the future.
Materials and Methods
Virus-like particles (VLPs)
A diverse panel of VLPs representing G1 and GII norovirus
strains and epitope mutants was assembled as previously reported
[13,17,75]. To design epitope exchange chimeric VLPs, we first
identified surface exposed residue clusters that varied over time.
Then, we synthesized a series of chimeric GII.4 ORF2 genes that
exchanged ‘‘putative’’ epitopes between GII.4.1987 and GII.4.2006
VLPs [43]. For all constructs except GII.4.2009 ORF2 [17], the
synthetically derived constructs were inserted directly into the VEE
replicon vector for the production of virus replicon particles (VRPs)
as previously described by our group. VLPs were expressed in VRP-
infected BHK cells and purified by velocity sedimentation in sucrose
and stored at 280uC. The GII.4.2009 (New Orleans [17]) VLPs
were expressed in the baculovirus system and purified by cesium
chloride gradient centrifugation and were the kind gift of Dr. Jan
Vinje, Centers for Disease Control and Prevention, Atlanta, GA.
VLP protein concentrations were determined by the BCA Protein
Assay (Pierce, Rockford, IL). VLP preparation purity averaged
.80% by SDS-Page analysis.
Human monoclonal antibody production
In early 2009, following written consent, blood samples from 63
donors were collected from adult healthy donors at the Lugano and
Basel Blood banks (Switzerland). Peripheral blood mononuclear cells
(PBMCs) and plasma were isolated and cryopreserved. On the day of
use, PBMCs from Donor 302898 (Figure 1), an individual born in
1948, were thawed and IgG+ memory B cells were isolated using
GII.4 Norovirus Human Monoclonal Antibodies
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CD22 microbeads (Miltenyi) followed by cell sorting, as described
[76]. Cells were immortalized at 5 cells/well in multiple cultures
using EBV in the presence of CpG oligodeoxynucleotide 2006
(Microsynth) and irradiated allogeneic PBMC. After 2 weeks, culture
supernatants were screened for the presence of norovirus-specific
mAbs by EIA against VLPs and positive cultures were cloned by
limiting dilution. Antibodies were recovered from supernatants and
purified using protein A affinity chromatography and finally desalted
against PBS using a HiTrap FastDesalting column.
EIAs
Human mAb reactivity was determined by EIA, as reported
[34]. Briefly, plates were coated at 1 mg/ml VLP in PBS before the
addition 1 mg/ml purified IgG or donor plasma (0.2%). Primary
antibody incubation was followed by anti-human IgG-alkaline
phosphatase and color development with pNPP substrate solution
(Sigma Chemicals, St. Louis, MO). Each step was followed by
washing with PBS-0.05% Tween-20 and all antibodies were
diluted in 5% dry milk in PBS-0.05% Tween-20. Data shown
represent the average of at least three replicates and are
representative of similar data from at least two independent trials.
Establishment of EIAs using new mAbs included PBS-coated wells
as negative controls and polyclonal anti-norovirus human sera as
positive controls. Antibodies were considered positive for reactivity
if the mean optical density after background subtraction for VLP-
coated wells was greater than three times the mean optical density
for PBS-coated wells [34]. For screening donor plasma samples, the
binding titers of plasma to respective coated VLPs were determined
by EIA as described above by measuring the plasma dilution
required to achieve 50% maximal binding (ED50). EIA reactivity to
GII.4.2006 P protein (amino acids 221–531 [21]) was measured
similarly to reactivity to VLP. GII.4.2006 P protein was the kind gift
of B.V. Prasad, Baylor College of Medicine, Houston, TX).
VLP-Carbohydrate ligand-binding antibody blockade assays
Pig Gastric Mucin Type III (PGM) (Sigma Chemicals) has been
validated as a substrate for NoV VLP antibody-blockade assays
[17]. PGM contains relatively high levels of H and A antigen and
more moderate levels of Lewis Y antigen [17]. All of the GII.4 VLPs
used in the blockade assays in this study bind to both PGM and
synthetic Bi-HBGA, and binding to PGM is consistent with
synthetic Bi-HBGA binding profiles for a-1,2-fucose (H antigen)
and a-1,4-fucose (Lewis antigen) containing molecules [13,17,77].
For blockade assays, PGM was solvated in PBS at 5 mg/ml and
coated onto EIA plates at 10 mg/ml in PBS for 4 hours and blocked
over night at 4uC in 5% dry milk in PBS-0.05% Tween-20. VLPs
(0.5 mg/ml) were pretreated with decreasing concentrations of test
mAb or donor plasma for 1 hour at room temperature before being
added to the carbohydrate ligand–coated plates for 1 hour. Bound
VLP was detected by a rabbit anti-GII norovirus polyclonal sera
made from hyperimmunization with either GII.4.2009 or a cocktail
of GII.4.1997, GII.3.1999, GII.1.1976, and GII.2.1976 VLPs,
followed by anti-rabbit IgG-HRP (GE Healthcare) and color
developed with 1-Step Ultra TMB ELISA HRP substrate solution
(Thermo-Fisher). The percent control binding was defined as the
binding level in the presence of antibody pretreatment compared to
the binding level in the absence of antibody pretreatment multiplied
by 100. All incubations were done at room temperature. Each step
was followed by washing with PBS-0.05% Tween 20 and all
reagents were diluted in 5% dry milk in PBS-0.05% Tween-20. All
antibodies were tested for blockade potential against the panel of
GII.4 VLPs at two-fold serial dilutions ranging from 0.08 to 2 mg/
ml. Additional concentrations of blockade antibodies were tested if
needed to complete the sigmoid dose-response curve. Blockade of
synthetic Bi-HBGAs (Glycotech, Gaithersburg, MD) assays were
done as described for PGM with the following exception. Bi-
HBGAs were bound to Neutri-avidin coated plates (Pierce) at
10 mg/ml for one hour prior to the addition of 1 mg/ml VLP for
1.5 h. Reported mean % control binding reflects the results of at
least two independent experiments with each dilution tested at least
in duplicate. An antibody was designated as a ‘‘blockade’’ antibody
for a VLP if at least 50% of control binding was inhibited by 2 mg/
ml antibody. Blockade data were fitted and EC50 values calculated
using Sigmoidal dose response analysis of non-linear data in
GraphPad Prism 5 (www.graphpad.com). EC50 values between
VLPs were compared using the One-way ANOVA with Dunnett
post test, when at least three values were compared or the unpaired
t-test when two values were compared. A difference was considered
significant if the P value was ,0.05. To test for antibody binding
that prevents detector antibody from binding to the VLP instead of
the VLP binding to the PGM, select blockade assays are performed
without using a detector antibody and instead developed directly
with an anti-human IgG-HRP. Antibodies tested this way give two
responses; 1) a bell-shaped response curve for antibodies that are
blockade and 2) a sigmoidal shaped curve for antibodies that are not
blockade. These data indicate that it is the amount of human mAb
that is directly blocking the VLP from binding to PGM. Of note,
VLP concentrations in blockade assays are in the low nanomolar
range and therefore cannot discriminate between antibodies with
sub-nanomolar affinities.
Hemagglutination inhibition assays
HAI assays were performed as reported [38,39,45]. VLPs at
50 ng/reaction were pretreated with antibody as described above
for the blockade assays before addition to O+ RBCs at 4uC,
pH 5.5. An HAI titer was determined as the lowest antibody
concentration that completely prevented NoV VLP-induced HA
by visualization.
Structural models of VLP P domains
The amino acid sequences of GII.4.1987, GII.4.2002, and
GII.4.2006 capsids were individually aligned to the VA387 P
domain sequence using Clustalx1.86 [78], and the GII.4.2002
domain dimer X-ray crystal structure (PDB accession: 2OBT) [16]
was used as a template for generating homology models.
Homology models were generated using the program Modeller
available via the Max Planck Institute Bioinformatics Toolkit
(http://toolkit.tuebingen.mpg.de/). The structural models were
analyzed and compared, and figures were generated using Mac
Pymol (Delano Scientific).
Supporting Information
Figure S1 NoV VLP EC50 (reciprocal dilution) in
individual plasma samples by VLP. EIA reactivity to
individual VLPs is color coded: White; EC50 dilution ,100,
Purple; EC50 dilution between 100–500, Blue; EC50 dilution
between 501–1999, Pink; EC50 dilution $2000. Monoclonal
antibodies were developed from Donor 302898, named NVB.
(PDF)
Figure S2 EIA Reactivity of NVB plasma and mAbs
against NoV VLPs. Columns present the mean OD of 0.2%
NVB plasma or 1 mg/ml mAb reactivity with immobilized VLP.
Panel A: Antibodies with broad genogroup II VLP reactivity.
Panel B. Antibodies with restricted GII.4 VLP reactivity. Bars are
SEM. Mean ODs above 3-fold background (dashed line) were
scored as positive.
(TIF)
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